Search results for "bioavailability"

showing 10 items of 301 documents

Biological monitoring of welders exposed to aluminium

2005

To evaluate an adequate strategy for biological monitoring of aluminium (Al), a group of 62 Al welders (age in 1999: 23-51 years, median 35 years) was surveyed annually from 1999 to 2003 by determination of pre- and post-shift Al in urine and plasma. Biomonitoring was supplemented by personal air measurements of the total dust concentration. The welders' internal exposure was compared to the exposure of 60 non-exposed assembly workers (age in 1999: 21-51 years, median: 36 years) who were surveyed in 1999, 2001 and 2003. Having a nearly constant dust exposure, median concentrations of Al in urine (Al in plasma) of the welders decreased from 40.1 microg/g to 19.8 microg/g creatinine (8.7 to 4…

AdultInhalation ExposureCreatinineChemistryDustAir Pollutants OccupationalGeneral MedicineUrineElimination kineticsMiddle AgedToxicologyBioavailabilitychemistry.chemical_compoundAnimal scienceOccupational ExposureEnvironmental chemistryBiomonitoringCorrelation analysisHumansWeldingDust exposureAluminumEnvironmental MonitoringToxicology Letters
researchProduct

Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans

2006

Abstract Objective The number of active pharmaceutical ingredients (API) undergoing inhibitable and saturable intestinal efflux is considerable. As a consequence, absorption and bioavailability may depend on the intestinal concentration profile of the drug and may vary as a function of dose and release rate of the drug from the dosage form. The impact of controlled versus immediate-release on the absorption of P-glycoprotein substrates is currently unknown. Thus, the main focus of the present study was a comparison of the pharmacokinetics of the P-gp model substrate talinolol following administration of immediate-release (IR) and controlled-release (CR) tablets to healthy human volunteers w…

AdultMaleActive ingredientChemistryPharmaceutical ScienceAbsorption (skin)PharmacologyCrossover studyControlled releaseDosage formBioavailabilityPropanolamineschemistry.chemical_compoundIntestinal AbsorptionSolubilityPharmacokineticsDelayed-Action PreparationsHumansFemaleATP Binding Cassette Transporter Subfamily B Member 1TabletsTalinololEuropean Journal of Pharmaceutical Sciences
researchProduct

The Influence of Chitosan on the Oral Bioavailability of Acyclovir-a Comparative Bioavailability Study in Humans

2015

Purpose The effects of chitosan hydrochloride on the oral absorption of acyclovir in humans were studied to confirm the absorption enhancing effects reported for in vitro and rat studies, respectively. Methods A controlled, open-label, randomized, 3-phase study was conducted in 12 healthy human volunteers. Zovirax 200 mg dispersible tablets co-administered with doses of 400 and 1000 mg chitosan HCl were compared with Zovirax only. Results The expected increased absorption of acyclovir was not observed. On the contrary, mean area under the plasma concentration-time curve (AUC0-12 h) and maximal plasma concentration (Cmax) decreased following concomitant chitosan intake (1402 versus 1017 and …

AdultMaleBioavailability StudyAcyclovirAdministration OralBiological AvailabilityPharmaceutical Science02 engineering and technologyAbsorption (skin)PharmacologyAntiviral Agents030226 pharmacology & pharmacyHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]Chitosan03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsbiopharmaceutics classification systemHumansMedicinePharmacology (medical)Chromatography High Pressure LiquidPharmacologyChitosanDrug Carriersbusiness.industryOrganic Chemistry021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystembiowaiverHealthy Volunteers3. Good healthBioavailabilitychemistryexcipient interactionsData Interpretation StatisticalMolecular MedicineFemaleChitosan hydrochloridebioavailability0210 nano-technologybusinesspharmacokineticsResearch PaperBiotechnologyBiological availabilityPharmaceutical Research
researchProduct

Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability

2008

Previous in vitro studies using Caco-2 cell monolayers suggested a possible interaction between green and black tea and folic acid at the level of intestinal absorption. The main purpose of the present study was to investigate a possible pharmacokinetic interaction between tea and folic acid in healthy volunteers. In an open-labeled randomized cross-over study, the pharmacokinetic interaction between tea and folic acid (0.4 mg and 5 mg) was investigated in healthy volunteers. Water was used as the reference drink. Subjects ingested 0.4 mg folic acid tablets with water, green or black tea (0.3 g extract/250 ml) or 5 mg folic acid tablets with water or green tea (0.3 g extract/250 ml). Blood …

AdultMaleBiological AvailabilityPharmaceutical SciencePharmacologyIntestinal absorptionFood-Drug InteractionsFolic AcidPharmacokineticsIn vivoHumansPharmacology (medical)Black teaImmunoassayPharmacologyCross-Over StudiesDose-Response Relationship DrugTeaChemistryfood and beveragesGeneral MedicineMiddle AgedCrossover studyBioavailabilityDose–response relationshipFolic acidArea Under CurveLuminescent MeasurementsVitamin B ComplexFemaleBiopharmaceutics & Drug Disposition
researchProduct

Atenolol interaction with aspirin, allopurinol, and ampicillin.

1983

Atenolol kinetics were investigated in six healthy subjects after 100 mg orally, as monotherapy a 6-day treatment began 48 hr later. After a therapy-free interval of 4 wk, the same subjects received the same dose of atenolol with 1 gm ampicillin, 500 mg aspirin, and with 300 mg allopurinol. Allopurinol and aspirin did not substantially alter the kinetics of atenolol. After a single oral dose of 100 mg atenolol combined with 1 gm ampicillin, the bioavailability of atenolol was reduced to 36 +/- 5% compared to 60 +/- 8% after monotherapy. During long-term treatment with atenolol and ampicillin the bioavailability of atenolol fell to 24% (P less than 0.01). Mean peak plasma levels were lowered…

AdultMaleCombination therapyUrinary systemAllopurinolPhysical ExertionAllopurinolBiological AvailabilityBlood PressurePharmacologyPropanolaminesHeart RateAmpicillinmedicineHumansPharmacology (medical)Drug Interactionscardiovascular diseasesPharmacologyAspirinAspirinChemistryAtenololBioavailabilityKineticsBlood pressureAtenololAmpicillinFemalecirculatory and respiratory physiologymedicine.drugClinical pharmacology and therapeutics
researchProduct

Relationship between rheological properties, in vitro release and in vivo equivalency of topical formulations of diclofenac.

2019

Determination of bioequivalence remains a challenge in generic topical drug development. To support pharmacokinetic studies, strategies to demonstrate microstructure sameness of the products being compared include in vitro evaluations, such as the comparison of rheological properties, droplet size and in vitro release rates. Nevertheless, defining the appropriate acceptance range to consider equivalence between test and reference formulation is complex. To shed more light into this issue, in vitro release and rheological properties were compared to in vivo bioequivalence data (systemic blood measurements within a clinical trial) after topical application of a single dose. Test and reference…

AdultMaleDiclofenacAdolescentAdministration TopicalPharmaceutical ScienceBiological Availability02 engineering and technologyBioequivalence030226 pharmacology & pharmacy03 medical and health sciencesYoung Adult0302 clinical medicineDiclofenacPharmacokineticsRheologyIn vivomedicineHumansMathematicsTopical drugCross-Over StudiesMiddle Aged021001 nanoscience & nanotechnologyIn vitroBioavailabilityTherapeutic EquivalencyArea Under CurveFemale0210 nano-technologyRheologyBiomedical engineeringmedicine.drugInternational journal of pharmaceutics
researchProduct

Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application

1994

Pharmacokinetics and bioavailability of benperidol were determined in 13 schizophrenic patients after acute administration of 6 mg benperidol as an intravenous (i.v.) bolus injection, orally as liquid, and orally as tablets using a partially randomized cross-over design. Drug plasma levels were determined by high performance liquid chromatography with electrochemical detection and subjected to model independent pharmacokinetic analyses. After i.v. dosing the geometric means (mean-g) were 3.2 min for the distribution half-life, 5.80 h for the elimination half-life (t1/2 beta), 4.21 l/kg for the distribution volume, 7.50 h for the mean residence time (MRT), and 0.50 l/(h*kg) for the clearance…

AdultMaleMetaboliteAdministration OralBiological AvailabilityPharmacologyHigh-performance liquid chromatographyBenperidolchemistry.chemical_compoundPharmacokineticsOral administrationmedicineHumansDistribution (pharmacology)PharmacologyCross-Over StudiesChemistryBenperidolMiddle AgedBioavailabilityInjections IntravenousSchizophreniaFemaleGeometric meanOxidation-ReductionHalf-Lifemedicine.drugPsychopharmacology
researchProduct

Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.

1983

With a new formulation, which made intravenous infusion of triamterene (TA) possible, plasma levels and urinary excretion rates of TA and its main metabolite (OH-TA-ester) were measured in a randomized, cross-over trial in 6 healthy volunteers given triamterene 10 mg i.v. and 50 mg p.o. TA and OH-TA-ester were determined by densitometric measurement of native fluorescence after thin layer chromatography. Distribution volumes of the central compartment of TA and OH-TA-ester were 1.49 l/kg and 0.11 l/kg, respectively. Terminal half-lives were 255 min for TA and 188 min for OH-TA-ester after i.v. administration. For TA total plasma clearance was 4.5 l/min and renal plasma clearance 0.22 l/kg. …

AdultMaleMetabolitemedicine.medical_treatmentBiological AvailabilityAbsorption (skin)PharmacologyFirst pass effectchemistry.chemical_compoundPharmacokineticsmedicineHumansPharmacology (medical)Infusions ParenteralPharmacologyTriamtereneChromatographyGeneral MedicineThin-layer chromatographyBioavailabilityKineticschemistryFemaleDiureticmedicine.drugTriamtereneEuropean journal of clinical pharmacology
researchProduct

The tomato sauce making process affects the bioaccessibility and bioavailability of tomato phenolics: A pharmacokinetic study

2013

Tomato sauce is the most commonly consumed processed tomato product worldwide, but very little is known about how the manufacturing process may affect the phenolic composition and bioavailability after consumption. In a prospective randomised, cross-over intervention study, we analysed the plasma and urinary levels of tomato phenolic compounds and their metabolites after acute consumption of raw tomatoes and tomato sauce, enriched or not with refined olive oil during production. Respectively, eleven and four phenolic metabolites were found in urine and plasma samples. The plasma concentration and urinary excretion of naringenin glucuronide were both significantly higher after the consumptio…

AdultMaleNaringeninFood HandlingBiological AvailabilityUrineAnalytical Chemistrychemistry.chemical_compoundSolanum lycopersicumPhenolsPharmacokineticsHumansProspective StudiesPhenolsFood scienceChromatographyfungifood and beveragesGeneral MedicineMiddle AgedBioavailabilitychemistryFemaleComposition (visual arts)GlucuronideFood ScienceOlive oilFood Chemistry
researchProduct

High-dose short-term administration of naringin did not alter talinolol pharmacokinetics in humans.

2015

Naringin is considered the major causative ingredient of the inhibition of intestinal drug uptake by grapefruit juice. Moreover, it is contained in highly dosed nutraceuticals available on the market. A controlled, open, randomized, crossover study was performed in 10 healthy volunteers to investigate the effect of high-dose naringin on the bioavailability of talinolol, a substrate of intestinal organic anion-transporting polypeptide (OATP)-mediated uptake. Following 6-day supplementation with 3 capsules of 350 mg naringin daily, 100mg talinolol were administered orally with 3 capsules of the same dietary supplement (1050 mg naringin) on the seventh day. This test treatment was compared to …

AdultMalefood.ingredientAdrenergic beta-AntagonistsPharmaceutical ScienceOrganic Anion TransportersPharmacologyPolymorphism Single NucleotideDosage formGrapefruit juicePropanolamineschemistry.chemical_compoundFood-Drug InteractionsYoung AdultNutraceuticalfoodPharmacokineticsHumansNaringinDosage FormsCross-Over StudiesDose-Response Relationship DrugChemistryCrossover studyBioavailabilityDietary SupplementsFlavanonesFemaleTalinololCitrus paradisiEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct